Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction
- 1 September 2003
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 285 (3) , H1229-H1235
- https://doi.org/10.1152/ajpheart.00207.2003
Abstract
Matrix metalloproteinase-2 (MMP-2) is prominently overexpressed both after myocardial infarction (MI) and in heart failure. However, its pathophysiological significance in these conditions is still unclear. We thus examined the effects of targeted deletion of MMP-2 on post-MI left ventricular (LV) remodeling and failure. Anterior MI was produced in 10- to 12-wk-old male MMP-2 knockout (KO) and sibling wild-type (WT) mice by ligating the left coronary artery. By day 28, MI resulted in a significant increase in mortality in association with LV cavity dilatation and dysfunction. The MMP-2 KO mice had a significantly better survival rate than WT mice (56% vs. 85%, P < 0.05), despite a comparable infarct size (50 ± 3% vs. 51 ± 3%, P = not significant), heart rate, and arterial blood pressure. The KO mice had a significantly lower incidence of LV rupture (10% vs. 39%, P < 0.05), which occurred within 7 days of MI. The KO mice exerted less LV cavity dilatation and improved fractional shortening after MI by echocardiography. The LV zymographic MMP-2 level significantly increased in WT mice after coronary artery ligation; however, this was completely prevented in KO mice. In contrast, the increase in the LV zymographic MMP-9 level after MI was similar between KO and WT mice. MMP-2 activation is therefore considered to contribute to an early cardiac rupture as well as late LV remodeling after MI. The inhibition of MMP-2 activation may therefore be a potentially useful therapeutic strategy to manage post-MI hearts.Keywords
This publication has 28 references indexed in Scilit:
- Fluvastatin, a 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor, Attenuates Left Ventricular Remodeling and Failure After Experimental Myocardial InfarctionCirculation, 2002
- Matrix Metalloproteinase Inhibition After Myocardial InfarctionCirculation Research, 2001
- Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarctionJournal of Clinical Investigation, 2000
- Matrix Metalloproteinase-2 Contributes to Ischemia-Reperfusion Injury in the HeartCirculation, 2000
- Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failureNature Medicine, 1999
- Delayed Reperfusion Alters Matrix Metalloproteinase Activity and Fibronectin mRNA Expression in the Infarct Zone of the Ligated Rat HeartJournal of Molecular and Cellular Cardiology, 1997
- Unaltered Secretion of β-Amyloid Precursor Protein in Gelatinase A (Matrix Metalloproteinase 2)-deficient MiceJournal of Biological Chemistry, 1997
- C-Reactive Protein as a Predictor of Infarct Expansion and Cardiac Rupture After a First Q-Wave Acute Myocardial InfarctionCirculation, 1997
- Effect of ramipril and losartan on collagen expression in right and left heart after myocardial infarctionMolecular and Cellular Biochemistry, 1996
- Regulation of collagen degradation in the rat myocardium after infarctionJournal of Molecular and Cellular Cardiology, 1995